SEARCH:   Advanced

Blood, 15 October 2007, Vol. 110, No. 8, pp. 2803-2810. Prepublished online as a Blood First Edition Paper on June 26, 2007; DOI 10.1182/blood-2006-11-055673. This Article Full Text (PDF) Supplemental Figures All Versions of this Article: blood-2006-11-055673v1 110/8/2803    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Chung, B. Articles by Weinberg, K. I Search for Related Content PubMed PubMed Citation Articles by Chung, B. Articles by Weinberg, K. I Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted November 2, 2006 Accepted June 4, 2007 Prevention of graft-versus-host disease by anti-IL-7R antibody Brile Chung, Eric P Dudl, Dullei Min, Lora Barsky, Nancy Smiley, and Kenneth I Weinberg* Pediatrics Division of Stem Cell Transplantation, Stanford University, Stanford, CA, United States Bone Marrow Transplantation, Childrens Hospital Los Angeles, Los Angeles, CA, United States * Corresponding author; email: kw1{at}stanford.edu. Graft-versus-host disease (GVHD) continues to be a serious complication that limits the success of allogeneic bone marrow transplantation (BMT). Using IL-7 deficient murine models, we have previously shown that IL-7 is necessary for the pathogenesis of GVHD. In the present study, we determined whether GVHD could be prevented by antibody-mediated blockade of IL-7 receptor (IL-7R) signaling. C57/BL6 (H2Kb) recipient mice were lethally irradiated and co-transplanted with T cell depleted (TCD) BM and lymph node (LN) cells from allogeneic BALB/c (H2Kd) donor mice. Following transplantation, the allogeneic BMT recipients were injected weekly with either anti-IL-7R antibody (100 µg/mouse/week) or PBS for 4 weeks. Anti-IL-7R antibody treatment significantly decreased GVHD-related morbidity and mortality, compared to placebo (30% to 80%). IL-7R blockade resulted in the reduction of donor CD4+ or CD8+ T cells in the periphery by day 30 post-transplantation. Paradoxically, the inhibition of GVHD by anti-IL-7R antibody treatment resulted in improved long-term thymic and immune function. Blockade of IL-7R by anti-IL-7R antibody resulted in elimination of alloreactive T cells, prevention of GVHD, and improvement of donor T cell reconstitution. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: IL-7: griffinesque role in GVHD Pavan Reddy Blood 2007 110: 2788. [Full Text] [PDF] This article has been cited by other articles: R. M. Dean, T. Fry, C. Mackall, S. M. Steinberg, F. Hakim, D. Fowler, J. Odom, J. Foley, R. Gress, and M. R. Bishop Association of Serum Interleukin-7 Levels With the Development of Acute Graft-Versus-Host Disease J. Clin. Oncol., December 10, 2008; 26(35): 5735 - 5741. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020